Displaying 46 - 60 of 653
Dr. Balajee is a graduate of the University of Madras (India) and completed her post doctoral training in Dr. Kieren Marr’s laboratory at the Fred Hutchinson Cancer Research Center, Seattle, US. Currently she leads the Molecular Epidemiology Unit within the Mycotic Diseases Branch at the Centers for Disease Control and Prevention.
Dr. Balajee’s dynamic research program is focused on public health mycology that includes studies on the molecular epidemiology of medically important fungi, specifically the genus Aspergillus. Another area of interest is understanding the role of mycotoxins, specifically aflatoxin elaborated by Aspergillus in mediating adverse health effects in humans. Dr. Balajee has published over 25 peer-reviewed articles and several book chapters and is committed to creating a learning environment for budding public health mycologists in her laboratory. Dr. Balajee is the convenor for an international working group on A. terreus to gather and disseminate scientific knowledge in this field and is a member of the working group on species concepts inAspergillus.
Key Contributions to recent literature:
Arun Balajee Ph.D.
Email [email protected]
Phone - 404 639 3337
My research focus lies in genetically dissecting those aspects of Aspergillus spp. that render them potent pathogens and superb natural product machines. My laboratory’s research includes elucidation of fungal sporulation and host/pathogen interactions; processes intimately linked to secondary metabolite (e.g. mycotoxin) production. My tactic has been to use the genetic model Aspergillus nidulans to elucidate important biological processes in this genus and then carry this information to the plant pathogens A. flavus and A. parasiticus and the human pathogen A. fumigatus. The former two pathogens contaminate seed crops worldwide with aflatoxin, the most potent naturally occurring carcinogen known. The latter pathogen is now tied with Candida as the most serious human mycopathogen in developed countries where it can cause invasive aspergillosis, a disease with a mortality rate ranging from 50 to 90%.
Areas of fungal biology that my lab has been central in developing include:
I. Genetic Regulation of Secondary Metabolism and the Role of Toxic Metabolites in Fungal Virulence.
II. Gene silencing processes.
III. Host/fungal signaling.
Professor of Genetics
I have carried out research on filamentous fungi such asAspergillus nidulans andPenicillium
Current research interests include the molecular genetics and genomics of secondary metabolism, and polar growth of filamentous fungi, especially Aspergillus nidulans and the opportunistic human and animal pathogen Aspergillus fumigatus.
Secondary metabolism studies have been focussed on the structure and function of non ribosomal peptide synthetases (NRPS), exemplified by ACV synthetase, which assembles the
Recent genome sequencing projects on A. nidulans and A. fumigatushave revealed an abundance of novel secondary metabolic gene clusters, and we are applying a combination of genetic and chemical approaches to determine their products, some of which have activity against mammalian cells.
Selected earlier publications
Selected recent publications
|William J. Steinbach||
William J. Steinbach
Assistant Professor , Division of Pediatric Infectious Diseases, Duke University,USA
Dr. Steinbach is a graduate of University of North Carolina School of Medicine and trained in Pediatrics at Stanford University. He later completed a pediatric infectious diseases fellowship at Duke University. He is an associate researcher at the Duke Clinical Research Institute.
Dr. Steinbach has published over 30 peer-reviewed articles and several book chapters, generally concerning fungal disease and antifungal agents. He is involved in several clinical trials of newer antifungal agents, including involvement with the NIAID Bacteriology and Mycoses Study Group. To focus on the issues of fungal disease and treatment in pediatrics, he is also the co-director of the Pediatric Fungal Network.
His basic science interests include in vitro, in vivo, and molecular exploration of A. fumigatus, focusing on mechanisms of pathogenesis as well as optimizing antifungal therapies. Dr. Steinbach’s clinical interest focuses on invasive aspergillosis diagnosis and management, as well as pediatric fungal infections and the unique characteristics they reveal. In an effort to unite his basic science and clinical interests, Dr. Steinbach is a co-chairman of the Advances Against Aspergillosis international conference (www.advancesagainstaspergillosis.org).
Recent key contributions to the literature:
Division of Pediatric Infectious Diseases
Tel +1 (919) 684-6335
David Paterson is a newly appointed Professor of Infectious Diseases at the University of Queensland, and Consultant Infectious Diseases Physician and Microbiologist at the Royal Brisbane and Women's Hospital. His prior appointment was Director of the Antibiotic Management Program at the University of Pittsburgh Medical Center. He is the author of more than 100 peer-reviewed publications in the field of infectious diseases and clinical microbiology. His specific areas of interest are in antibiotic resistance in Gram negative bacilli and optimisation of antimicrobial use in the critically ill and the immunocompromised. He was the winner of the American Society for Microbiology's Merck Irving Siegal Award awarded at ICAAC 2000 and has been an advisor to the Clinical and Laboratory Standards Institute (CLSI).
Professor of Infectious Diseases at the University of Queensland
|David W. Denning||
David W. Denning
Professor of Infectious Diseases in Global Health and Consultant in Infectious Diseases and Medical Mycology, Wythenshawe Hospital and University of Manchester and President of the Global Action Fund for Fungal Infections.
Graduate of Guy's Hospital, University of London, 1980. Clinical training in internal medicine, infectious diseases, microbiology, paediatrics and haematology in London, Glasgow and California (1980-1990). Research training at the MRC Clinical Research Centre, Harrow, UK (1985-87) and Stanford University, California, USA (1987-1990). Granted a personal chair by Manchester University in 2005.
My clinical interests are in fungal diseases, immunocompromised patients and complex hospital infection problems.
My research interests relate to antifungal susceptibility testing and resistance, pathogenesis of invasive aspergillosis, clinical studies of antifungal agents, Aspergillusgenomics and the burden of fungal infections globally and in different countries.
In addition to continuing clinical practice and research, I was instrumental in starting a biotechnology company called F2G. F2G has identified several new promising antifungal drug candidates , one of which is shortly to be studied in human volunteers. I retain a very small number of F2G shares, but no longer consult for it.
In 2006, I founded Myconostica, a molecular diagnostics spin-out of The University of Manchester. Myconostica developed and commercialised rapid real-time molecular diagnostic tests for Aspergillus and Pneumocystis, before being acquired by Lab21 in May 2011. IÂ advise Trinity Biotech (who now handle Myconostica products) on clinical aspects of fungal diagnosis as a consultantI also advise T2 Biosystems (diagnostics), GSK (Vaccines) and give talks on behalf of Astellas, Pfizer and Gilead. In 2013,I became President of the Global Action Fund for Fungal infections.
Key contributions to the literature:
David W. Denning FRCP FRCPath FIDSA FMedSci